Nicox SA: Promising Financial Stability and Clinical Advancements Drive Buy Rating

Nicox SA (0RCQ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a €1.00 price target.

Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Nicox SA’s promising financial and clinical outlook. The company has secured a flexible equity line of financing, which extends its cash runway into the fourth quarter of 2025, providing financial stability. This agreement allows Nicox to manage its cash flow effectively while preparing for significant upcoming clinical milestones.
Additionally, Nicox is advancing in its clinical trials, with the Phase 3 Denali trial for NCX 470 in glaucoma patients fully enrolled and expected to report results in the third quarter of 2025. The recent data from the Phase 3 Mont Blanc trial demonstrated that NCX 470 is statistically superior in lowering intraocular pressure compared to latanoprost, meeting efficacy standards for U.S. approval. These clinical advancements, coupled with a favorable valuation and a high probability of approval for NCX 470, underpin Selvaraju’s optimistic outlook and Buy rating for Nicox SA.